Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to -$7.9 million.
- Mangoceuticals' Net Income towards Common Stockholders fell 24502.46% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.1 million, marking a year-over-year decrease of 10910.26%. This contributed to the annual value of -$8.7 million for FY2024, which is 548.38% up from last year.
- According to the latest figures from Q3 2025, Mangoceuticals' Net Income towards Common Stockholders is -$7.9 million, which was down 24502.46% from -$5.4 million recorded in Q2 2025.
- Mangoceuticals' Net Income towards Common Stockholders' 5-year high stood at -$1.8 million during Q3 2023, with a 5-year trough of -$7.9 million in Q3 2025.
- In the last 3 years, Mangoceuticals' Net Income towards Common Stockholders had a median value of -$2.4 million in 2024 and averaged -$3.3 million.
- In the last 5 years, Mangoceuticals' Net Income towards Common Stockholders soared by 2412.15% in 2024 and then tumbled by 24502.46% in 2025.
- Over the past 3 years, Mangoceuticals' Net Income towards Common Stockholders (Quarter) stood at -$2.6 million in 2023, then grew by 24.12% to -$1.9 million in 2024, then plummeted by 306.05% to -$7.9 million in 2025.
- Its Net Income towards Common Stockholders stands at -$7.9 million for Q3 2025, versus -$5.4 million for Q2 2025 and -$4.8 million for Q1 2025.